改善成人2型糖尿病血糖控制的数字行为治疗应用随机对照试验
该随机对照试验纳入669例HbA1c 7至<11%的2型糖尿病成人,比较数字认知行为治疗应用BT-001与对照应用在标准治疗基础上的疗效。90天后BT-001组HbA1c变化为-0.28%,对照组为+0.11%,组间差异0.39%(P<0.0001),且HbA1c下降与完成模块数平行。两组均无归因于应用使用的不良事件,数字治疗可能提供可扩展的治疗选择。
要点
- BT-001组90天HbA1c变化-0.28%,对照组+0.11%,组间差异0.39%(P<0.0001)。
- HbA1c下降与完成应用模块数平行(趋势P<0.0001)。
- 两组均无归因于应用使用的不良事件,无器械不良效应报告。
核心结论
- 随机分配至BT-001组的患者相对于对照组在90天时HbA1c显著更低。
- 数字治疗可能为2型糖尿病患者提供可扩展的治疗选择。
研究设计与样本
- 随机对照试验,纳入669例完成应用引导的2型糖尿病成人,HbA1c为7至<11%,随机分配接受数字认知行为治疗应用BT-001或对照应用,均在标准治疗管理基础上。
主要发现
- 基线HbA1c在BT-001组为8.2%、对照组为8.1%。
- 90天后HbA1c变化BT-001组为-0.28%(95%CI -0.41, -0.15),对照组为+0.11%(95%CI -0.02, 0.23),组间差异0.39%(P<0.0001)。
- HbA1c下降与完成应用模块数平行(趋势P<0.0001)。
- 两组均无归因于应用使用的不良事件,无器械不良效应报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of a digital therapeutic application (app) delivering cognitive behavioral therapy (CBT) designed to improve glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Adults with type 2 diabetes and an HbA1c of 7 to <11% were randomly assigned to receive access to a digital therapeutic app delivering CBT (BT-001) or a control app, both on top of standard of care management. CBT is an established form of psychological treatment that endeavors to identify and change unhelpful thinking patterns. The primary study end point was treatment group difference in mean HbA1c change from baseline to 90 days. RESULTS: Among 669 randomly assigned subjects who completed app onboarding, the mean age was 58 years, BMI 35 kg/m2, 54% were female, 28% Black, and 16% Latino. Baseline HbA1c was 8.2 and 8.1% in the BT-001 and control groups, respectively. After 90 days of app access, change in HbA1c was -0.28% (95% CI -0.41, -0.15) in the BT-001 group and +0.11% (95% CI -0.02, 0.23) in the control group (treatment group difference 0.39%; P < 0.0001). HbA1c reduction paralleled exposure to the therapeutic intervention, assessed as the number of modules completed on the app (P for trend <0.0001). No adverse events in either group were attributed to app use and no adverse device effects reported. CONCLUSIONS: Patients randomly assigned to the BT-001 arm relative to the control arm had significantly lower HbA1c at 90 days. The digital therapeutic may provide a scalable treatment option for patients with type 2 diabetes.
引用
- Hsia J, Guthrie NL, Lupinacci P, et al. Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes. Diabetes Care. 2022. PMID: 36181554. doi:10.2337/dc22-1099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。